AbbVie won a first-of-its-kind approval for a non-surgical treatment aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.

Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19.

The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic and included hundreds of abstracts, posters and presentations.

The U.S. government entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine.

Britain’s AstraZeneca clinched expanded regulatory backing for two medications, including one for the blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.

The U.S. Food and Drug Administration approved AstraZeneca Plc’ drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.